Summary:
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of XXXX in Migraine Prevention in Children and Adolescents ≥ 6 to <18 years of age.
Qualified Participants Must:
• Have 6 or more pediatric migraine headache
•
Be at least 6 years old and at most 17 years old
•
Be a non-smoker
•
14 or less headache days during the Observation Period